Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners.

Steve ProwackiAboud AndrewO'Gorman Thomas

Published in: Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists (2021)

Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.

Keyphrases

chronic pain
primary care

healthcare
hyaluronic acid

quality improvement
pain management

human health
risk assessment